

Author	Type of record	Dose range (mg/day)	Length of intervention (weeks)	Randomised to duloxetine	Randomised to placebo	Baseline HDRS-17 scores duloxetine mean (SD)	Baseline HDRS-17 scores Control mean (SD)	Participant* age (yr) duloxetine mean (SD)	Participant* age (yr) control mean (SD)	Exclusion of participants with chronic/treatment resistant depression	Placebo washout period
Balchin 2012	Published article	60	8	157	152	23.2 (4.2)	23.1 (4.6)	45.3 (12.0)	43.4 (12.5)	yes	yes
Boukenger 2014	Published article	60	8	147	139	14.7		45.6 (13.6)	46.1 (13.1)	no	no
Cutler 2009	Published article	60	6	151	157	25.2 (2.6)	25.2 (2.7)	40.2 (12.5)	42.3 (11.5)	yes	yes
Delwa 2002 A	Published article + CSR	60	9	123	122	21.4 (4.1)	21.1 (3.7)	42.4 (13.7)	42.3 (12.6)	yes	yes
Delwa 2002 B	Published article + CSR	60	9	128	139	20.3 (3.4)	20.46 (3.38)	41 (13.5)	41 (15.0)	yes	yes
Delwa 2004 A	Published article + CSR	80	8	95	46	18.9 (3.6)	18.9 (3.6)	43.1 (11.1)	43.7 (12.2)	yes	yes
Delwa 2004 B	Published article + CSR	120	8	93	47	20.2 (3.4)	19.9 (3.6)	44.7 (11.1)	43.7 (12.2)	yes	yes
Goldstein 2004 A	Published article + CSR	40	8	86	44	18.7 (5.9)	17.2 (5.1)	40.7 (10.0)	40.1 (12.9)	yes	yes
Goldstein 2004 B	Published article + CSR	80	8	91	45	17.8 (4.6)	17.2 (5.1)	40.9 (11.9)	40.1 (12.9)	yes	yes
Goldstein 2002	Published article + CSR	120, variable dose as physicians could refuse dose escalation for individual participants	8	70	70	18.4 (4.0)	19.2 (5.0)	42.3 (10.8)	41.4 (13.3)	yes	yes
Kosova 2012	Published article	60	8	151	145	22.3 (3.5)	22.7 (3.8)	70.9 (5.5)	70.3 (4.4)	yes	no
Mahabeshwarhar 2015 A	Published article	60	8	152	161	NR	NR	43.4 (12.2)	42.4 (12.5)	yes	yes
Mahabeshwarhar 2015	Published article	60	8	152	153	NR	NR	42.7 (14.4)	42.6 (13.8)	yes	no
Mahabeshwarhar 2015 B	Published article	60	8	210	194	NR	NR	45.7 (11.5)	45 (12.1)	yes	no
Nienberg 2007	Published article	60	8	273	137	17.6 (4.8)	17.7 (5.2)	41.1 (11.6)	42.8 (12.3)	yes	yes
Oakes 2012 A	Published article	60	12	257	127	22.8 (4.3)	22.8 (5.7)	42.2 (12.2)	43.7 (10.5)	yes	no
Oakes 2012 B	Published article	60	12	261	131	22.8 (4.5)	22.9 (4.9)	44.7 (12.2)	43.8 (11.9)	yes	no
Perakhia 2006 A	Published article + CSR	60	8	93	49	21.3 (3.5)	20.6 (3.7)	46.5 (12.7)	44.7 (10.1)	yes	yes
Perakhia 2006 B	Published article + CSR	120	8	103	50	21.4 (4.4)	20.6 (3.7)	44 (10.8)	44.7 (10.1)	yes	yes
Rasani 2007	Published article	60	8	207	104	18.8 (4.6)	18.9 (4.6)	72.6 (5.7)	73.3 (5.7)	No	yes
Robinson 2014	Published article	60	12	249	121	19.4 (5.6)	19.3 (5.8)	73 (8.2)	73.1 (5.6)	yes	yes
Touren 2009	Published article	60	8	159	164	22 (2.3)	24 (3.9)	39 (12.3)	39 (13.9)	No	no
F.U.MC-HMAJ (A)	Abbreviated CSR	5	8	130	42	23.6 (3.9)	23.2 (3.7)	43.1 (12.1)	41.3 (12.4)	No	yes
F.U.MC-HMAJ (B)	Abbreviated CSR	10	8	129	42	23.7 (3.5)	23.2 (3.7)	42.4 (10.1)	41.3 (12.4)	No	yes
F.U.MC-HMAJ (C)	Abbreviated CSR	20	8	131	42	23.9 (3.6)	23.2 (3.7)	41.5 (11.4)	41.3 (12.4)	No	yes
HBI-MC-HGAC	Clinical study summary	120	4	35	35	17 (4.7)	18.6 (4.7)	38	42	no	yes
F.U.MC-HMAQ (B)	Clinical study report	120, variable dose as a dose range of 20-60 mg BID was used	8	82	75	17.8 (5.2)	18.3 (5.6)	39.8 (9.8)	41.4 (11.8)	no	yes
I195BA	Clinical study report synopsis	60	6	133	139					yes	no
F.U.MC-HMAAT a (A)	Clinical study report	40	8	91	45	17.5 (5.2)	17.8 (4.7)	43.3 (15.2)	43.2 (14.5)	yes	yes
F.U.MC-HMAAT a (B)	Clinical study report	80	8	94	45	17.6 (5.2)	17.8 (4.7)	43.7 (14.0)	43.2 (14.5)	yes	yes
F.U.MC-HMAQ (A)	Clinical study report	20, variable dose as dose adjustment was done for patients with adverse events or no response 10-30 mg/ day	10	27	26	20.8 (3.3)	20.9 (4.2)	43.3 (10.5)	42.7 (9.3)	yes	Yes, in some participants
F.U.MC-HMAQ (B)	Clinical study report	20	10	26	26		21 (4.5)	37.7 (9.7)	37.8 (10.2)	yes	Yes, in some participants
F.U.MC-HMAH	Clinical study report	20-30	10	89	88	20.4 (3.2)	20.6 (2.9)			yes	yes
Hgwehi 2009 (A)	Published article*	40	6	75	73	20.4	20.4	-	-	yes	yes
Hgwehi 2009 (B)	Published article*	60	6	75	73	20.4	20.4	-	-	yes	yes
NCT01145716	Clinical trial registry	60	6	47	44	NR	NR	39.9	38.4	yes	NR
NR= not reported											
SD= standard deviation											
CSR= clinical study report											
*data from Cipriani et al 2018											